已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

危险系数 阿替唑单抗 内科学 置信区间 免疫疗法 人口 临床终点 医学 膀胱癌 肿瘤科 生物标志物 辅助治疗 佐剂 癌症 随机对照试验 无容量 生物 环境卫生 生物化学
作者
Thomas Powles,Zoe J. Assaf,Nicole N. Davarpanah,Romain Banchereau,Bernadett Szabados,Kobe Yuen,Petros Grivas,Maha Hussain,Stéphane Oudard,Jürgen E. Gschwend,Peter Albers,Daniel Castellano,Hiroyuki Nishiyama,Siamak Daneshmand,Shruti Sharma,Bernhard Zimmermann,Himanshu Sethi,Alexey Aleshin,Maurizio Perdicchio,Jingbin Zhang
出处
期刊:Nature [Nature Portfolio]
卷期号:595 (7867): 432-437 被引量:593
标识
DOI:10.1038/s41586-021-03642-9
摘要

Minimally invasive approaches to detect residual disease after surgery are needed to identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) holds promise as a biomarker for molecular residual disease and relapse1. We evaluated outcomes in 581 patients who had undergone surgery and were evaluable for ctDNA from a randomized phase III trial of adjuvant atezolizumab versus observation in operable urothelial cancer. This trial did not reach its efficacy end point in the intention-to-treat population. Here we show that ctDNA testing at the start of therapy (cycle 1 day 1) identified 214 (37%) patients who were positive for ctDNA and who had poor prognosis (observation arm hazard ratio = 6.3 (95% confidence interval: 4.45–8.92); P < 0.0001). Notably, patients who were positive for ctDNA had improved disease-free survival and overall survival in the atezolizumab arm versus the observation arm (disease-free survival hazard ratio = 0.58 (95% confidence interval: 0.43–0.79); P = 0.0024, overall survival hazard ratio = 0.59 (95% confidence interval: 0.41–0.86)). No difference in disease-free survival or overall survival between treatment arms was noted for patients who were negative for ctDNA. The rate of ctDNA clearance at week 6 was higher in the atezolizumab arm (18%) than in the observation arm (4%) (P = 0.0204). Transcriptomic analysis of tumours from patients who were positive for ctDNA revealed higher expression levels of cell-cycle and keratin genes. For patients who were positive for ctDNA and who were treated with atezolizumab, non-relapse was associated with immune response signatures and basal–squamous gene features, whereas relapse was associated with angiogenesis and fibroblast TGFβ signatures. These data suggest that adjuvant atezolizumab may be associated with improved outcomes compared with observation in patients who are positive for ctDNA and who are at a high risk of relapse. These findings, if validated in other settings, would shift approaches to postoperative cancer care. The authors report on prospective exploratory analyses of circulating tumour DNA in an urothelial carcinoma immunotherapy clinical trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
5秒前
楠楠发布了新的文献求助10
5秒前
甜菜图书馆完成签到,获得积分10
6秒前
专注向雪完成签到 ,获得积分10
8秒前
zhaoxx完成签到 ,获得积分10
8秒前
微笑大神发布了新的文献求助10
9秒前
9秒前
XHQ完成签到 ,获得积分10
9秒前
Alice发布了新的文献求助10
11秒前
12秒前
脑洞疼的应助被DearWhite采纳,获得10
12秒前
浪漫小窗完成签到,获得积分10
12秒前
文献阅读小王完成签到 ,获得积分10
15秒前
ty发布了新的文献求助30
15秒前
Pz迷惑发布了新的文献求助10
17秒前
GJing完成签到 ,获得积分10
20秒前
22秒前
永恒完成签到 ,获得积分10
23秒前
无逾期发布了新的文献求助10
25秒前
gggoblin完成签到,获得积分10
26秒前
王思聪完成签到 ,获得积分10
26秒前
zzzfun完成签到,获得积分10
26秒前
27秒前
小匹夫完成签到 ,获得积分10
28秒前
小兔子完成签到 ,获得积分10
28秒前
Owen的应助被七七四十九采纳,获得10
29秒前
29秒前
科研通AI65的应助被z104采纳,获得10
30秒前
小臣发布了新的文献求助10
31秒前
32秒前
Owen的应助被微笑大神采纳,获得10
32秒前
Karry完成签到 ,获得积分10
32秒前
SiO2完成签到 ,获得积分0
32秒前
xpm完成签到 ,获得积分10
35秒前
科研通AI6.3的应助被crystal采纳,获得10
36秒前
Judy发布了新的文献求助10
36秒前
36秒前
NexusExplorer的应助被ty采纳,获得10
37秒前
有朋自远方来完成签到,获得积分10
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189808
求助须知:如何正确求助?哪些是违规求助? 9576985
关于积分的说明 21850907
捐赠科研通 7787770
什么是DOI,文献DOI怎么找? 3435793
关于科研通互助平台的介绍 2559825
邀请新用户注册赠送积分活动 2482680